Evidence map›Paper›PMID 26993470›Full record

ReviewCurrent atherosclerosis reports2016

Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Jeffrey E Alfonsi, Robert A Hegele, Steven E Gryn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeffrey E AlfonsiDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Jeffrey.alfonsi@lhsc.on.ca.
Robert A HegeleDepartment of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Steven E GrynDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, 339 Windermere Road, London, ON, Canada, N6A 5A5. steven.gryn@lhsc.on.ca.

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Lipid-lowering medications, particularly statins, have been a popular target for pharmacogenetic studies. A handful of genes have shown promise for predicting response to therapy from the perspective of lipid lowering, as well as myopathy. A number of genes have been implicated and have biological plausibility based on their involvement with the pharmacokinetics or pharmacodynamics of statins or other lipid-lowering medications. The level of confidence and replication of these findings varies, although several associations are likely true. Novel classes of lipid-lowering therapy have opened up new possibilities in the treatment of severe inherited forms of dyslipidemia, making the identification of such mutations an important pharmacogenetic predictor of failure of standard therapy, with potential response to novel therapy. Advances in next-generation sequencing technology bring the application of pharmacogenetics even closer to routine clinical practice.

Indexed as

HomozygoteHumansHyperlipidemiasHypolipidemic AgentsLipid MetabolismLipoproteinsHypolipidemic AgentsLipoproteinsDyslipidemiasHydroxymethylglutaryl-CoA reductase inhibitorsHypolipidemic agentsPharmacogenetics

Identifiers

PMID26993470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.